SFDA approves registration of Pemazyre for cholangiocarcinoma

November 11, 2025

Saudi Gazette reportRIYADH — The Saudi Meals and Drug Authority (SFDA) has authorized the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with regionally superior or metastatic cholangiocarcinoma.

Supply hyperlink

Is Casemiro leaving Manchester United? The Purple Devils linked to former Actual Madrid market goal

Saudi Arabia, Kuwait signal 4 MoUs for bolstering bilateral ties

Popular

SFDA approves registration of Pemazyre for cholangiocarcinoma

Subscribe

Saudi Arabia Intercepts Houthi Drone Earlier than It Enters Makkah Airspace

Houthi Missile and Drone Assaults Deliver New Safety Issues Close to Makkah

barq closes $329.5 million Sequence A funding spherical

13 Civilians Injured as Houthis Assault Three Saudi Cities

Saudi Arabia and the value of greatness

More like this
Related

Saudi Arabia Intercepts Houthi Drone Earlier than It Enters Makkah Airspace

Houthi Missile and Drone Assaults Deliver New Safety Issues Close to Makkah

barq closes $329.5 million Sequence A funding spherical

13 Civilians Injured as Houthis Assault Three Saudi Cities

About us

The latest

Saudi Arabia Intercepts Houthi Drone Earlier than It Enters Makkah Airspace

Houthi Missile and Drone Assaults Deliver New Safety Issues Close to Makkah

barq closes $329.5 million Sequence A funding spherical

Subscribe

SFDA approves registration of Pemazyre for cholangiocarcinoma

Subscribe

More like thisRelated

About us

The latest

Subscribe

More like this
Related